Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATFORM: Breyanzi Combinations in R/R B-Cell Malignancies
NCT03310619Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2017
- Primary completion
- Feb 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of lisocabtagene maraleucel in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma (HGBCL), non-Hodgkin lymphoma (NHL), sponsored by Celgene Corporation. Started Dec 2017; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)primary mediastinal large B-cell lymphoma (PMBCL)high grade B-cell lymphoma (HGBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03310619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03310619.